Recent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy
Ehab Takrori, Mahmoud Abdulmajid, Deepthi Devagudi, Ramsha Sohail, Zaynah Sadiq, Chris Berneau, Andrew Shenouda, Rakesh Adelli, Supriya Peshin, Sakshi Singal · 2026
Read Recent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy by Ehab Takrori, Mahmoud Abdulmajid, Deepthi Devagudi, Ramsha Sohail, Zaynah Sadiq, Chris Berneau, Andrew Shenouda, Rakesh Adelli, Supriya Peshin, Sakshi Singal (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13207714.txt.
Description
Ehab Takrori and co-authors review, in a 2026 paper, fresh advances against pancreatic and bile duct cancers. Both cancers kill at high rates because they surface late, vary a lot between patients, and resist standard drugs. The review gathers trial results and lab work that now guide care.
For pancreatic cancer, gains include sharper surgery timing, wider gene testing, and drugs aimed at the KRAS gene fault. For bile duct cancers, gene profiling has opened targeted drugs for faults in genes such as FGFR2, IDH1, and HER2. Immune drugs help select bile duct cases but few pancreatic ones. Blood tests for tumor DNA scraps are rising as tools to track response and spot resistance early. Care now leans on early gene profiling for each patient.
Catalog record
| CREATOR | Ehab Takrori, Mahmoud Abdulmajid, Deepthi Devagudi, Ramsha Sohail, Zaynah Sadiq, Chris Berneau, Andrew Shenouda, Rakesh Adelli, Supriya Peshin, Sakshi Singal |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 81 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |